In general, antibodies are known to play an important role in neutralising the virus and provide protection to the host against re-infection. USA, India, and Brazil account for most of the cases worldwide with India recording about 13.52 million cases and 1.70 million deaths. As of April 12, 2021, more than 135 million individuals were infected with SARS-CoV-2 and 2.92 million SARS-CoV-2-associated deaths were reported. Since its emergence in December 2019, from Wuhan city of China, SARS-CoV-2 virus has spread rapidly throughout the world. The lower persistence of anti-nucleocapsid SARS-CoV-2 antibody may not be the exact phenomenon as those cases were still seropositive against spike protein and help in neutralising the virus. Out of 76 cases, 30 cases (39.47%) became seronegative in qualitative assay, although all the sera samples (100%) remained positive when tested in quantitative assay. We found a waning of antibodies against nucleocapsid antigen protein but not a complete disappearance by the end of 16 weeks. We recorded the antibody magnitude of these individuals 10 times between September 2020 and February 2021. We collected serum samples from these individuals for 16 weeks with a frequency of weekly and fortnightly during each follow-up and tested them in two CLIA-based platforms (Abbott Architect i1000SR and Roche Cobas e411) for testing SARS-CoV-2 antibodies both qualitatively and quantitatively. In this observational cohort study, we have followed up the 76 individuals who tested positive for SARS-CoV-2 infection by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) for 16 weeks (post-enrolment) to record the periodic changes in titre, concentration, clinical growth and persistence of naturally developed SARS-CoV-2 antibodies. Study of dynamicity and durability of naturally developed antibodies against SARS-CoV-2 are of great importance from an epidemiological viewpoint. Coronavirus disease-19 (COVID-19) pandemic became the greatest public health challenge globally.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |